Lilly: patients treated with Taltz showed no progression of radiographic damage
Eli Lilly announced that the majority of patients with active psoriatic arthritis, or PsA, treated with Taltz exhibited either no progression or minimal progression of radiographic structural joint damage through 52 weeks of treatment. Detailed results from the extension period of the SPIRIT-P1 trial will be presented in an oral presentation today during the Annual European Congress of Rheumatology 2017. Patients treated with Taltz at both dosing regimens experienced either no progression or minimal radiographic progression of structural joint damage as measured by the change from baseline in the van der Heijde modified Total Sharp Score for PsA at 52 weeks. No progression or minimal radiographic progression of structural joint damage was also observed for patients who switched from placebo or adalimumab to either dosing regimen of Taltz after the 24-week treatment period.